Integumen PLC - Rinocloud subsidiary wins "One To Watch" IT award
AIM share code: SKIN
21 October 2019
("Integumen" or "Company")
Integumen's Rinocloud subsidiary wins "One To Watch" IT award
Rinocloud, a wholly-owned subsidiary of Integumen, has won the TechLeaders19 IT award, sponsored by
The Tech Leaders awards, which are in their 13th year, shine a light on those people who are leading the charge for the technology community and paving the way for the continued success of the technology sector in
Fin Murray MD of Rinocloud and Executive Director of Integumen commented:
"We are so honoured to have received this IT Leadership award in recognition of the Rinocloud team's creation of a disruptive drug discovery process for skin diseases such as psoriasis, eczema, acne and dandruff.
We wouldn't have been able to do it without the support from partner scientific research institutes APC Microbiome at the
| || |
+44 (0) 7340 055 648
| || |
+44 (0) 113 370 8974
| || || |
+44 (0) 20 3657 0050
Integumen is a vertically integrated product and services company for skin related diseases, treatments and therapies with three business units:
· Labskin AI's technology platform incorporates artificial intelligence within clinical research for medical device, pharmaceuticals, cosmeceuticals and related life science test services. Labskin allows skincare, healthcare, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.
· Wound pHase is developing skin and wound care products using its proprietary wound dressing technology. Working in collaboration with CBD providers creating a CBD infused diabetic wound care product range.
Stoer-for-men skin products e-commerce division offers a range of skincare products derived from 5 natural super-ingredient plant extracts specifically for men to reduce the signs of ageing and is also used as a control for client testing within Labskin laboratories.
The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.
About RNS Reach announcements
RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
This information is provided by RNS, the news service of the
Quick facts: Integumen
Market Cap: £22.11 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE